April 14, 2019 08:00 PM EDTUpdated May 30, 11:45 AM
R&D

Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

John Carroll

Editor & Founder

In a race to ex­pand mar­ket share against two top ri­vals in the di­a­betes field, J&J just scored one in the win col­umn. And they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times